- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Vol. 26/No. 9 | Oncology Live®
Targeted Therapies Move the Needle in NSCLC
October 08, 2025
Article
Benjamin P. Levy, MD, FASCO, discusses how new targeted approaches are affecting the NSCLC treatment landscape.
Personalization Drives Next Wave of Metastatic Castration-Sensitive Prostate Cancer Treatment
October 07, 2025
Article
A panel of experts discusses the effort to personalize treatment approaches in metastatic castration-sensitive prostate cancer.
Sacituzumab Tirumotecan Plus Pembrolizumab Is Set to Be Evaluated in TNBC
October 06, 2025
Article
Sacituzumab tirumotecan plus pembrolizumab is currently being evaluated for select patients with TNBC in the phase 3 TroFuse-012 trial.
Older Cancer Clinical Trials May Continue to Offer Relevant Lessons Learned
October 05, 2025
Article
From the Editor
Maurie Markman, MD, details the lessons learned following results from older clinical trials within the oncology space.
GPC3 Offers Highly Specific Target in HCC
October 03, 2025
Article
GPC3 has the potential to be targeted in patients with HCC with reduced off-target toxicities compared with other targeted agents.
Sunvozertinib Approval Fills Treatment Gap in Pretreated EGFR Exon 20–Mutant NSCLC
September 26, 2025
Article
Lyudmila A. Bazhenova, MD, discusses the FDA approval of sunvozertinib (Zegfrovy) in patients with EGFR exon 20–mutant non–small cell lung cancer.
IHC Testing Could Serve as Surrogate to NGS for Early Detection of TP53-Mutant MDS/AML
July 29, 2025
Article
Results of an observational study showed that immunohistochemistry could act as a biomarker for the early detection of TP53‐mutant MDS or AML.
IHC Testing May Bridge Gaps With NGS for Early Identification, Intervention in TP53-Mutant MDS and AML
July 28, 2025
Article
Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the next steps for validating IHC as a biomarker for TP53 mutations in MDS and AML.
IHC Testing May Enable Expedited Identification of TP53-Mutant MDS and AML
July 24, 2025
Article
Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the use of IHC testing for earlier identification of TP53 mutations in MDS and AML.
Cellular Therapies Begin to Make Their Mark in Solid Tumors
July 24, 2025
Article
OncLive spoke with experts working to develop cellular therapies in solid tumors to gain insights into their current standing and future in the space.